INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institut
University of Manchester
Mánchester, Reino UnidoPublications en collaboration avec des chercheurs de University of Manchester (55)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment
HEPATOBILIARY SURGERY AND NUTRITION
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
2021
-
A novel nonlinear filter through constructing the parametric Gaussian regression process
Nonlinear Dynamics, Vol. 105, Núm. 1, pp. 579-602
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Leukemia, Vol. 35, Núm. 12, pp. 3585-3588
-
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic
Expert Opinion on Investigational Drugs, Vol. 30, Núm. 4, pp. 377-388
-
Variational Bayesian inference for the identification of FIR systems via quantized output data
Automatica, Vol. 132
2020
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
2019
-
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 229-240
-
Comparative genomics of the major parasitic worms
Nature Genetics, Vol. 51, Núm. 1, pp. 163-174
-
Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature
Reumatologia Clinica, Vol. 15, Núm. 1, pp. 34-42
-
The search for noise-induced cochlear synaptopathy in humans: Mission impossible?
Hearing Research, Vol. 377, pp. 88-103
-
Zoledronate in the prevention of Paget's (ZiPP): Protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone
BMJ Open, Vol. 9, Núm. 9
2018
-
Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412
-
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia
British Journal of Haematology, Vol. 182, Núm. 3, pp. 373-383
2017
2016
-
Addressing misuse and diversion of opioid substitution medication: Guidance based on systematic evidence review and real-world experience
Journal of Public Health (United Kingdom), Vol. 38, Núm. 3, pp. e368-e374